Multicomponent Staphylococcal Vaccine Antigens
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines against Staphylococcus aureus infections, including those targeting S. aureus, have failed to demonstrate protective efficacy in Phase III trials due to antibiotic resistance and immune evasion mechanisms, particularly the immune evasion properties of S. aureus which interfere with adaptive immune responses.
Innovation Solution
An immunogenic composition comprising Staphylococcal antigens such as ClfA, Hla, SpA, and capsular polysaccharides from S. aureus serotypes 5 and 8, potentially conjugated to carrier proteins, combined with adjuvants like QS21 and 3D-MPL, to enhance immune response and vaccine efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines targeting single antigens are used, then manufacturing is simpler, but protective efficacy is insufficient due to immune evasion mechanisms
Solution Approach 1:
The patent combines multiple staphylococcal antigens (ClfA, Hla, SpA, and capsular polysaccharides from serotypes 5 and 8) into a single multicomponent vaccine formulation. This merging of multiple antigenic targets addresses the immune evasion mechanisms of S. aureus by presenting diverse epitopes that can elicit broader immune responses, thereby improving protective efficacy despite the increased compositional complexity
Solution Approach 2:
The vaccine employs a composite formulation containing multiple protein antigens and polysaccharide antigens in specific combinations. This composite approach leverages the synergistic effects of different antigen types (protein and polysaccharide) to overcome bacterial immune evasion strategies, achieving enhanced reliability through material composition rather than simple antigenic equivalence
2Reliability
If antibiotic treatment is used, then immediate therapeutic effect is achieved, but antibiotic resistance develops rendering treatment ineffective
Solution Approach 1:
The patent converts the harmful effect of antibiotic resistance into a beneficial alternative by developing a vaccine that provides long-term protective immunity. Instead of relying on antibiotics that face resistance challenges, the vaccine harnesses the immune system's natural defenses to prevent infection, effectively transforming the problem of antibiotic failure into an opportunity for immunoprophylaxis
3Object-affected harmful factors
If SpA is present in wild-type form, then natural immune evasion occurs, but modified SpA can be used to reduce harmful immune interference
Solution Approach 1:
The patent applies local quality modification by specifically altering the SpA antigen's Fc-binding capability while preserving other functional properties. The modified SpA retains its ability to serve as an immunogen and elicit immune responses, but its harmful Fc-binding activity that interferes with opsonophagocytic clearance is reduced or eliminated, creating a localized functional change that benefits vaccine efficacy
Data Source
AI summary
The invention provides an immunogenic composition comprising staphylococcal antigens, containing protein antigens and conjugates of capsular polysaccharides, n particular Hla, ClfA, SpA and conjugates of capsular polysaccharides. Adjuvanted formulations are also provided. The invention may find use in the prevention and treatment of staphylococcal infections, in particular S. aureus infection and disease.